Efficacy and safety of thrice weekly DOTS in tuberculosis patients with and without HIV co-infection: an observational study

Richa Vashishtha, Krishna Mohan, Bhagteshwar Singh, Satish K Devarapu, Vishnubhatla Sreenivas, Sanjay Ranjan, Deepak Gupta, Sanjeev Sinha, Surendra K Sharma, Richa Vashishtha, Krishna Mohan, Bhagteshwar Singh, Satish K Devarapu, Vishnubhatla Sreenivas, Sanjay Ranjan, Deepak Gupta, Sanjeev Sinha, Surendra K Sharma

Abstract

Background: Despite the latest World Health Organization guidelines advocating daily therapy in HIV-TB co-infected individuals, there are few recent studies comparing outcomes of thrice-weekly anti-tuberculosis treatment in HIV-positive and HIV-negative patients with TB. The present study sets out to compare TB treatment outcomes in these two groups in the Indian national programme, which currently involves thrice-weekly therapy for all, regardless of HIV status.

Methods: HIV-positive and HIV-negative were consecutively screened for enrolment into this prospective observational study, carried out at the All India Institute of Medical Sciences hospital, New Delhi, India, between 2006 and 2010. Patients were given short-course thrice-weekly rifampicin-based therapy, with all HIV-positive patients being started on highly active antiretroviral therapy at least 14 days after commencing TB treatment. Patients were regularly followed-up for 24 months after completion of treatment.

Results: 150 HIV-positive, 155 HIV-negative patients were enrolled consecutively for the study. Significantly higher treatment success (93.5% vs. 76.7% at end of treatment, p < 0.001) and lower mortality (2.8% vs. 21.6% on follow up, p < 0.001) were observed in HIV-negative patients. No significant difference was found in treatment failure (p = 0.16), sputum smear (p = 0.58) and culture conversion (p = 0.55), and non-serious adverse event incidence (p = 0.851) between the two groups. Low baseline CD4 cell count (<100 cells/ mm3) was the only predictor of mortality in HIV-TB patients (odds ratio 8 · 43, p = 0 · 013).

Conclusions: Thrice-weekly anti-tuberculosis therapy is more effective in HIV-negative than in HIV-positive patients. However, outcomes in this HIV co-infected cohort were found to be similar to those reported previously with daily therapy, with no safety concerns. This should prompt further study into whether intermittent or daily therapy should be used universally in resource-poor settings, using large well executed randomised controlled trials.

Trial registration: NCT No. 00698334.

Trial registration: ClinicalTrials.gov NCT00698334.

Figures

Figure 1
Figure 1
Study profile.

References

    1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009–1021. doi: 10.1001/archinte.163.9.1009.
    1. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool KQ. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362:697–706. doi: 10.1056/NEJMoa0905848.
    1. World Health Organization (WHO) Treatment of tuberculosis: Guidelines. 4th ed. Geneva: WHO Press; 2010.
    1. De Jong BC, Israelski DM, Corbett EL, Small PM. Clinical management of tuberculosis in the context of HIV infection. Annual Rev Med. 2004;55:283–301. doi: 10.1146/annurev.med.55.091902.103753.
    1. Perlman DC, Leung CC, Yew WW. Treatment of tuberculosis in HIV-infected patients: we need to know more. Am J Respir Crit Care Med. 2007;175(11):1102–1103. doi: 10.1164/rccm.200702-248ED.
    1. American Thoracic Society (ATS), Centers for Disease Control and Prevention (CDC), Infectious Diseases Society of America (IDSA) Treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603–662.
    1. Dlodlo RA, Fujiwara PI, Enarson DA. Should tuberculosis treatment and control be addressed differently in HIV-infected and –uninfected individuals? Eur Respir J. 2005;25:751–757. doi: 10.1183/09031936.05.10090404.
    1. Sterling TR, Alwood K, Gachuhi R, Coggin W, Blazes D, Bishai WR, Chaisson RE. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS. 1999;13:1899–1904. doi: 10.1097/00002030-199910010-00012.
    1. Chaisson RE, Clermont HC, Holt EA, Cantave M, Johnson MP, Atkinson J, Davis H, Boulos R, Quinn TC, Halsey NA. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med. 1996;154(4):1034–1038. doi: 10.1164/ajrccm.154.4.8887603.
    1. Kassim S, Sassan-Morokro M, Ackah A, Abouya LY, Digbeu H, Yesso G, Coulibaly IM, Coulibaly D, Whitaker PJ, Doorly R, Vetter KM, Brattegaard K, Gnaore E, Greenberg AE, Wiktor SZ, De Cock KM. Two-year follow-up of persons with HIV-1 and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS. 1995;9(10):1185–1192. doi: 10.1097/00002030-199510000-00011.
    1. Nahid P, Gonzalez LC, Rudoy I. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med. 2007;175(11):1199–1206. doi: 10.1164/rccm.200509-1529OC.
    1. Swaminathan S, Narendran G, Venkatesan P, Illiayas S, Santhanakrishnan R, Menon PA, Padmapriyadarsini C, Ramachandran R, Chinnaiyan P, Suhadev M, Sakthivel R, Narayanan PR. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: randomized clinical trial. Am J Respir Crit Care Med. 2010;181:743–751. doi: 10.1164/rccm.200903-0439OC.
    1. Perriens JH, St Louis ME, Mukadi YB, Brown C, Prignot J, Pouthier F, Portaels F, Willame JC, Mandala JK, Kaboto M, Ryder RW, Roscigno G, Piot P. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med. 1995;332:779–784. doi: 10.1056/NEJM199503233321204.
    1. El Sadr WM, Perlman DC, Matts JP, Nelson ET, Cohn DL, Salomon N, Olibrice M, Medard F, Chirgwin KD, Mildvan D, Jones BE, Telzak EE, Klein O, Heifets L, Hafner R. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Clin Infect Dis. 1998;26(5):1148–1158. doi: 10.1086/520275.
    1. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet. 2004;364:1244–1251. doi: 10.1016/S0140-6736(04)17141-9.
    1. Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, Menzies D. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis. 2010;50(9):1288–1299. doi: 10.1086/651686.
    1. Johnson JL, Okwera A, Nsubuga P, Nakibali JG, Whalen CC, Hom D, Cave MD, Yang ZH, Mugerwa RD, Ellner JJ. Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Uganda-Case Western Reserve University Research Collaboration. Int J Tuberc Lung Dis. 2000;4(11):1032–1040.
    1. Okwera A, Johnson JL, Luzze H, Nsubuga P, Kayanja H, Cohn DL, Nunn P, Ellner JJ, Whalen CC, Mugerwa RD. Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala. Int J Tuberc Lung Dis. 2006;10(1):39–44.
    1. Schwander S, Rusch-Gerdes S, Mateega A, Lutalo T, Tugume S, Kityo C, Rubaramira R, Mugyenyi P, Okwera A, Mugerwa R. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tuber Lung Dis. 1995;76(3):210–218. doi: 10.1016/S0962-8479(05)80007-3.
    1. Sharma SK, Dhooria S, Prasad KT, George N, Ranjan S, Gupta D, Sreenivas V, Kadhiravan T, Miglani S, Sinha S, Wig N, Biswas A, Vajpayee M. Outcomes of antiretroviral therapy in a northern Indian urban clinic. Bull World Health Organ. 2010;88:222–226. doi: 10.2471/BLT.09.068759.
    1. Karmakar S, Sharma SK, Vashishta R, Sharma A, Ranjan S, Gupta D, Sreenivas V, Sinha S, Biswas A, Gulati V. Clinical characteristics of tuberculosis-associated immune reconstitution inflammatory syndrome in North Indian population of HIV/AIDS patients receiving HAART. Clin Dev Immunol. 2011;2011:239021.
    1. National Tuberculosis Association of the USA. Diagnostic standards and classification of tuberculosis. New York: National Tuberculosis Association; 1961.
    1. World Health Organization. Laboratory services in tuberculosis control II. Microscopy. Italy: WHO Press; 1999.
    1. Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare. Tuberculosis control in India. New Delhi: Elsevier; 2005.
    1. National AIDS Control Organisation (NACO) Antiretroviral therapy guidelines for HIV-infected adults and adolescents including post-exposure prophylaxis. New Delhi: NACO; 2007.
    1. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol. 1997;35:907–914.
    1. Daniel OJ, Alausa OK. Treatment outcome of TB/HIV positive and TB/HIV negative patients on directly observed treatment, short course (DOTS) in Sagamu. Nigeria. Niger J Med. 2006;15(3):222–226.
    1. Korenromp EL, Scano F, Williams BG, Dye C, Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis. 2003;37:101–112. doi: 10.1086/375220.
    1. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y, Marcy O, Chan S, Prak N, Kim C, Lak KK, Hak C, Dim B, Sin CI, Sun S, Guillard B, Sar B, Vong S, Fernandez M, Fox L, Delfraissy JF, Goldfeld AE. CAMELIA (ANRS 1295–CIPRA KH001) Study Team. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365(16):1471–1481. doi: 10.1056/NEJMoa1013911.
    1. Dhingra VK, Rajpal S, Aggarwal N, Aggarwal JK, Shadab K, Jain SK. Adverse drug reactions observed during DOTS. J Commun Dis. 2004;236:251.
    1. Mwandumba HC, Squire SB. Fully intermittent dosing with drugs for treating tuberculosis in adults. Cochrane Database Syst Rev. 2001;4:CD000970.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe